The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.

Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...

Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...

Moderna Inc.'s stock tumbled 4% Thursday, after a report that health officials are reviewing a contract the company won from the Biden administration to support its efforts to develop a bird-flu ...

US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...

Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...

Health-care company stocks declined. Moderna shares fell after reports that federal health officials are re-evaluating its $590 million contract to help develop a bird-flu vaccine. Shares of Teladoc ...

Nvidia is helping to prop up the U.S. stock market, and indexes are drifting higher. The S&P 500 rose 0.4% in early Thursday ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested Nvidia earnings and Trump's latest tariff threats.